🇺🇸 FDA
Patent

US 11026947

ALK2 inhibitors and methods for inhibiting BMP signaling

granted A61KA61K31/519A61K31/5377

Quick answer

US patent 11026947 (ALK2 inhibitors and methods for inhibiting BMP signaling) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/519, A61K31/5377, A61K31/551, A61K31/675